Carol Spillane

Jun 14, 2024 | bmjopen.bmj.com | Niamh Byrne |Sarah McGarrigle |Geraldine Prizeman |Carol Spillane

DiscussionThis scoping review has mapped evidence relevant to cancer risk-management DAs that are applicable to female BRCA mutation carriers without a personal history of cancer. Specifically, we have identified and described the features of cancer risk-management DAs for this population and reported on the efficacy testing of these DAs where this has been conducted.

May 2, 2024 | ejso.com | Niamh Byrne |Sarah McGarrigle |Carol Spillane |Amanda Drury |Elizabeth Connolly |Anne-Marie Brady | +1 more

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.